Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367156 · ClinicalTrials.gov registry record · Phase 2
Dexamethasone in Controlling Dyspnea in Patients With Cancer
A Phase 2 study of Malignant Neoplasm and Dyspnea, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 3
- Study locations
NCT03367156: Active Phase 2 study of Malignant Neoplasm and Dyspnea, sponsored by M.D. Anderson Cancer Center.
NCT03367156 is a Phase 2 study of Malignant Neoplasm and Dyspnea that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 135 participants, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03367156, a Phase 2 study of Malignant Neoplasm and Dyspnea, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies how well dexamethasone works in controlling dyspnea in patients with cancer. Dexamethasone may help control dyspnea (shortness of breath) and improve lung function and quality of life in cancer patients.
Primary Outcome
The average dyspnea intensity over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10. The total score ranged from 0-10 where higher scores indicate worse dyspnea. The change in Dyspnea scores between Baseline and Day 7 were measured. Linear model analysis was used for analysis.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Dexamethasone
Study Locations (3)
Texas
- Lyndon B. Johnson Hospital - Houston
- Harris Health System Settegast Health Center - Houston
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2017-12-04 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03367156 still lists
NCT03367156 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03367156 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03367156 about?
NCT03367156 is a clinical study titled "Dexamethasone in Controlling Dyspnea in Patients With Cancer". This phase II trial studies how well dexamethasone works in controlling dyspnea in patients with cancer. Dexamethasone may help control dyspnea (shortness of breath) and improve lung function and quality of life in cancer patients.
What is the current status of trial NCT03367156?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2017-12-04. Estimated completion is 2025-12-31.
What conditions does trial NCT03367156 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Dyspnea.
What interventions are being tested in trial NCT03367156?
The interventions under investigation include: Placebo (OTHER), Questionnaire Administration (OTHER), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT03367156?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03367156 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03367156's enrollment target sits among peer trials
135 26th of 59 higher than 34 of 59 other Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Intraoperative Tumor Margin Identification With ICG Dye Imaging
RECRUITING · Phase 2
-
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
RECRUITING · Phase 2
-
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
RECRUITING · Phase 2
-
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI